SlideShare una empresa de Scribd logo
1 de 25
Descargar para leer sin conexión
Clobazam
7-Chloro- 1-methyl- 5-phenyl- 1,5-
  benzodiazepine- 2,4(3H)-dione
INTRODUCTION
• synthesized in 1972 by modification of the
  1,4-diazepine structure
• The resulting 1,5 structure retained 20% of
  the the anxiolytic activity of diazepam,10-15 %
  of diazepam's sedative effects .
• introduced as an anti-anxiety agent about
  half as potent as diazepam and producing less
  psychomotor side-effects than diazepam.
• later found to have major antiepileptic effects
CHEMISTRY

• white hygroscopic powder with MW 300.73.
• It has a bitter taste, is relatively insoluble in
  water
• cannot be given as intravenous or intramuscular
  injection.
• It is a weak organic acid and forms water-soluble
  salts at acidic pH.
• At physiological pH its lipid solubility is about 40%
  of that of diazepam
Mode of action
• Clobazam exerts its anxiolytic and
  anticonvulsant action at the benzodiazepine
  binding site of the Gamma-aminobutyric acid
  A (GABA -A) receptor complex by increasing
  the likelihood of opening of the ligand-gated
  Cl~ ion channel in response to given
  concentration of GABA.
• less affinity for the ω1-allosteric binding site on the
  GABAA receptor compared to the 1,4-benzodiazepines.
• selective affinity for the ω2 site, where it has agonistic
  activity.
• action at a lower affinity membrane site which
  probably involves an increase in the population of
  sodium channels in the inactive state, limiting the
  repetitive firing of neurones.
• A decrease of voltage-sensitive Ca conductance is also
  observed, limiting Ca(++) entry presynaptically and
  decreasing neurotransmitter release
Pharmacokinetics

•  absorbed rapidly and almost completely.
• Mean absorption half-life is 20 min.
• It is unaffected by age or sex.
• The rate of absorption is reduced when the drug
  is taken with or after meals, but the extent of
  absorption is not .
• The drug is highly lipophilic and, after
  absorption, is rapidly distributed in fat and
  cerebral grey matter.
• Maximal plasma concentration after a single dose is seen
  after 1-4 h
• half-lives varies from 11 to 77 h in healthy subjects, with
  the longest half-life in the elderly .
• The half-life of clobazam's major
  metabolite, Ndesmethylclobazam is even longer, about 50
  h.
• At clinical doses , plasma concentration of the metabolite
  (300-3500ng/mL) is usually 10-fold greater than clobazam
  concentrations (20-350 ng/mL) .
• good correlation between plasma concentration and dose
  in the individual patient but large interindividual variations.
• Measurements of serum levels, however, have not been
  found useful clinically.
• Plasma protein binding of the benzodiazepines
  varies from nearly 99% for diazepam to 70% for
  alprazolam.
• Clobazam protein binding is 83%.
• The protein bound fraction is independent of
  plasma concentration of clobazam
• only changed by lowered protein content, which
  may be of importance in hepatic and renal
  diseases and other conditions with lowered
  protein, e.g. in the elderly.
Drug interactions

•    has a complex pattern of interactions, with marked interindividual
    variability.
•   increase or decrease in the blood levels of
    phenobarbital, phenytoin or carbamazepine .
•   Phenytoin toxicity in patients on maximal tolerable phenytoin
    doses when clobazam was added
•    levels of all enzyme-inducing antiepileptic drugs can alter in
    susceptible patients.
•   The combination of valproate in doses of 1500-2000 mg and
    clobazam leads to an increase in serum valproate levels often with
    toxic-confusional states
•    These rather unpredictable interactions may be the explanation
    for the aversion to clobazam shown by some patients with chronic
    epilepsy on antiepileptic polytherapy.
• Clobazam levels are generally lower and norclobazam
  levels higher in patients who are comedicated with
  enzyme-inducing antiepileptic drugs.
• Comedication with carbamazepine seems to induce
  the epoxidation of this drug
• Conversely, it has also been reported that clobazam
  levels can be raised in bitherapy with
  phenobarbital, phenytoin and carbamazepine .
• Concomitant administration of alcohol and cimetidine
  can also lead to a significant increase in clobazam
  levels.
Biotransformation
• Clobazam is metabolized to least 12 metabolites.
• biotransformation of clobazam is by oxidation in the liver to
  desmethylclobazam (norclobazam), an active metabolite.
• Norclobazam may be responsible for the effects of clobazam .
  serum concentrations are usually over 10-fold higher than the
  parent drug.
• Studies in baboons have shown antiepileptic effects 5-6 h after IV
  infusion, by which time clobazam plasma concentrations have fallen
  to low levels.
• the lipophilicity of norclobazam is lower than that of
  clobazam, and the affinity for the benzodiazepine receptor is more
  than 10-fold lower than that of clobazam.
• Desmethylclobazam is further metabolized by conjugation and
  excreted in bile as glucuronate and in bile and urine as the sulphate
Clobazam
Toxicity

• sedation, development of tolerance and
  withdrawal symptoms can limit the use of 1,4
  benzodiazepines in chronic treatment of epilepsy,
• clobazam has less detrimental effects on
  psychomotor performance than these drugs .
• Impairment on a few cognitive tests, mainly
  retrieval processes and mental rapidity has been
  reported .
• Muscle fatigue or weakness is an effect apparent
  in dynamic work situations where a disorderly
  recruitment of motor units is seen .
• Significant toxicity includes
  sedation, dizziness, headache, nausea, amnesia, ataxia and
  blurred vision or diplopia.
• In chronic institutionalized patient populations increased
  irritability, depression and disinhibition occurs and
  behaviour disturbance may be seen. .
• Drowsiness and dizziness were the most common side-
  effects.
• Gelastic seizures,Urticaria ,Rashes,are rare side effects
• side-effects were mild and transient, and seems well
  tolerated.
• The plasma concentration of the metabolite norclobazam is
  increased significantly in polytherapy, and this may be the
  cause of some of the sedative side-effects
Clobazam
Tolerance
• Tolerance or 'escape' is usually measured as an increase of
  seizure frequency in the last half of a treatment period,
• Tolerance is increased by high doses, and decreased by
  intermittent treatment
• In patients with temporal lobe epilepsy tolerance was
  found to be increasing slowly from 3% after 1 month to
  35% after 2 years and did not seem to increase further
• Used as monotherapy in childhood epilepsy, tolerance was
  noted in7 .5%, as compared to 4.3% for carbamazepine and
  6.7% for phenytoin monotherapy .
• Tolerance to sedation develops more quickly than
  tolerance to the anticonvulsant or anxiolytic effects
withdrawal
• Withdrawal symptoms with
  irritability, restlessness and difficulty to
  concentrate appears in 5-10% during the first
  14 days after termination of treatment.
• Tapering will in most cases prevent this.
Clobazam
Antiepileptic effectiveness

• tried in patients with refractory epilepsy of long standing
  as an addition to other antiepileptic treatment.
• Patients of all ages, aetiologies and seizure types
  responded.
• Some consider partial seizures to do best, and others
  secondarily generalized attacks.
• It has been claimed that patients with symptomatic
  epilepsy, most often with partial seizures without
  secondary generalization and without mental
  retardation, respond best to clobazam , but this is an
  uncontrolled observation which has not been replicated
adjunctive therapy in
• complex partial seizures
• myoclonic,
• myoclonic-absent,
• simple partial,
• non-status absence seizures
Open studies reported a beneficial and even
  astounding effect in
• non-convulsive status,
• startle seizures ,
• Lennox-Gastaut syndrome
• alcoholic withdrawal seizures ,
 Studies of clobazam used as monotherapy are
  very few.
 Clobazam has, however, been used in open
  studies as the only drug in benign childhood
  partial epilepsy and found of value even in
  carbamazepine-resistant cases .
Uncontrolled observations (as well as routine clinical
  experience) show good efficacy
• acute epilepsy,
• clusters,
• serial seizures
• prophylaxis (e.g. on days when it is important to avoid
  a seizure such as when travelling, taking
  examinations, interviews, etc.).
• Clobazam is the drug of first choice for such
  intermittent therapy
• intermittent therapy in catamenial epilepsy
Dose and clinical therapeutics

• 5 to 140 mg/day.
• There is now general agreement that doses between 10
  and 20 mg/day (in adults) are usually best,
• few patients who continue to have seizures respond better
  to higher doses,
• Dose adjustments are not usually needed in patients
  comedicated with other antiepileptic drugs.
• The frequency of side-effects increases sharply with higher
  doses (above 30mg/day).
• The usual daily dose for acute prophylaxis is lOmg.
• Clobazam withdrawal should be carried out slowly in a
  staged fashion.
Clobazam

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Benzodiazipines
Benzodiazipines  Benzodiazipines
Benzodiazipines
 
ANTIDEPRESSANTS
ANTIDEPRESSANTSANTIDEPRESSANTS
ANTIDEPRESSANTS
 
anti-psychotic drugs
anti-psychotic drugsanti-psychotic drugs
anti-psychotic drugs
 
Anti psychotic drugs
Anti psychotic drugsAnti psychotic drugs
Anti psychotic drugs
 
Rifampicin
RifampicinRifampicin
Rifampicin
 
anxiolytics
anxiolyticsanxiolytics
anxiolytics
 
Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors (MAOIs)Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors (MAOIs)
 
Antiepileptics
Antiepileptics Antiepileptics
Antiepileptics
 
ANTIDEPRESSANTS
ANTIDEPRESSANTSANTIDEPRESSANTS
ANTIDEPRESSANTS
 
Dopamine
DopamineDopamine
Dopamine
 
Anti parkinsonism drugs by dr.mahi yeruva
Anti parkinsonism drugs by dr.mahi yeruvaAnti parkinsonism drugs by dr.mahi yeruva
Anti parkinsonism drugs by dr.mahi yeruva
 
Carbamazepine
CarbamazepineCarbamazepine
Carbamazepine
 
Antianxiety drugs
Antianxiety drugsAntianxiety drugs
Antianxiety drugs
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Dopamine
DopamineDopamine
Dopamine
 
Sedatives & hypnotics
Sedatives & hypnoticsSedatives & hypnotics
Sedatives & hypnotics
 
Clinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agentsClinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agents
 
Anticholinergic drugs - pharmacology
Anticholinergic drugs - pharmacologyAnticholinergic drugs - pharmacology
Anticholinergic drugs - pharmacology
 
Antiepileptics
AntiepilepticsAntiepileptics
Antiepileptics
 
Levodopa+carbidopa
Levodopa+carbidopaLevodopa+carbidopa
Levodopa+carbidopa
 

Similar a Clobazam

Tues 11am wrobel anticonvulsant pipeline
Tues 11am wrobel anticonvulsant pipelineTues 11am wrobel anticonvulsant pipeline
Tues 11am wrobel anticonvulsant pipelineNCProvidersCouncil
 
Anti-epileptics
Anti-epilepticsAnti-epileptics
Anti-epilepticsMrunalAkre
 
pharmacology of Antiparkinsonism final.ppt
pharmacology of Antiparkinsonism final.pptpharmacology of Antiparkinsonism final.ppt
pharmacology of Antiparkinsonism final.pptNorhanKhaled15
 
Anti epileptics-pharmacology and guidelines
Anti epileptics-pharmacology and guidelines Anti epileptics-pharmacology and guidelines
Anti epileptics-pharmacology and guidelines Navya devireddy
 
Carbamazepine public
Carbamazepine publicCarbamazepine public
Carbamazepine publicjulielive
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
 
carbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdfcarbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdfChintuCH1
 
Antipsychotics, chemistry and pharmacokinetics
Antipsychotics, chemistry and pharmacokineticsAntipsychotics, chemistry and pharmacokinetics
Antipsychotics, chemistry and pharmacokineticsDomina Petric
 
Adverse effects of antipsychotic drugs
Adverse effects of antipsychotic drugsAdverse effects of antipsychotic drugs
Adverse effects of antipsychotic drugsDomina Petric
 
Status Epilepticus
Status EpilepticusStatus Epilepticus
Status EpilepticusJack Frost
 
antiepilepticdrugs2-230402112455-c370050b (1).pdf
antiepilepticdrugs2-230402112455-c370050b (1).pdfantiepilepticdrugs2-230402112455-c370050b (1).pdf
antiepilepticdrugs2-230402112455-c370050b (1).pdfRwapembeStephen
 
Antiepileptic drugs
Antiepileptic drugs Antiepileptic drugs
Antiepileptic drugs Karun Kumar
 
Newer antiepileptic drugs
Newer antiepileptic drugsNewer antiepileptic drugs
Newer antiepileptic drugsFariha Shikoh
 
Pharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasePharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasebubuni7386
 
Dopamine receptor agonists
Dopamine receptor agonistsDopamine receptor agonists
Dopamine receptor agonistsDomina Petric
 
Management of Epilepsy, GTCS,
 Management of Epilepsy, GTCS, Management of Epilepsy, GTCS,
Management of Epilepsy, GTCS,ankitamishra1402
 

Similar a Clobazam (20)

Tues 11am wrobel anticonvulsant pipeline
Tues 11am wrobel anticonvulsant pipelineTues 11am wrobel anticonvulsant pipeline
Tues 11am wrobel anticonvulsant pipeline
 
Anti-epileptics
Anti-epilepticsAnti-epileptics
Anti-epileptics
 
pharmacology of Antiparkinsonism final.ppt
pharmacology of Antiparkinsonism final.pptpharmacology of Antiparkinsonism final.ppt
pharmacology of Antiparkinsonism final.ppt
 
Anti epileptics-pharmacology and guidelines
Anti epileptics-pharmacology and guidelines Anti epileptics-pharmacology and guidelines
Anti epileptics-pharmacology and guidelines
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Anti epilepsy
Anti epilepsyAnti epilepsy
Anti epilepsy
 
Carbamazepine public
Carbamazepine publicCarbamazepine public
Carbamazepine public
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
carbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdfcarbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdf
 
Antipsychotics, chemistry and pharmacokinetics
Antipsychotics, chemistry and pharmacokineticsAntipsychotics, chemistry and pharmacokinetics
Antipsychotics, chemistry and pharmacokinetics
 
Adverse effects of antipsychotic drugs
Adverse effects of antipsychotic drugsAdverse effects of antipsychotic drugs
Adverse effects of antipsychotic drugs
 
Status Epilepticus
Status EpilepticusStatus Epilepticus
Status Epilepticus
 
antiepilepticdrugs2-230402112455-c370050b (1).pdf
antiepilepticdrugs2-230402112455-c370050b (1).pdfantiepilepticdrugs2-230402112455-c370050b (1).pdf
antiepilepticdrugs2-230402112455-c370050b (1).pdf
 
Antiepileptic drugs
Antiepileptic drugs Antiepileptic drugs
Antiepileptic drugs
 
Newer antiepileptic drugs
Newer antiepileptic drugsNewer antiepileptic drugs
Newer antiepileptic drugs
 
Benzodiazipines Dr-Z Pharmacy Practice
Benzodiazipines Dr-Z Pharmacy Practice Benzodiazipines Dr-Z Pharmacy Practice
Benzodiazipines Dr-Z Pharmacy Practice
 
Pharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasePharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's disease
 
Dopamine receptor agonists
Dopamine receptor agonistsDopamine receptor agonists
Dopamine receptor agonists
 
Management of Epilepsy, GTCS,
 Management of Epilepsy, GTCS, Management of Epilepsy, GTCS,
Management of Epilepsy, GTCS,
 
CASE PRESENTATION BDZ.pptx
CASE PRESENTATION BDZ.pptxCASE PRESENTATION BDZ.pptx
CASE PRESENTATION BDZ.pptx
 

Más de Srirama Anjaneyulu (20)

Refractory pediatric epilepsy ,Management
Refractory pediatric epilepsy ,ManagementRefractory pediatric epilepsy ,Management
Refractory pediatric epilepsy ,Management
 
Vertigo
VertigoVertigo
Vertigo
 
Epileptic encephalopathy -EEG
Epileptic encephalopathy -EEGEpileptic encephalopathy -EEG
Epileptic encephalopathy -EEG
 
Thalamic lesions Radiology diagnose your self
Thalamic lesions Radiology diagnose your selfThalamic lesions Radiology diagnose your self
Thalamic lesions Radiology diagnose your self
 
HEADACHE
HEADACHE HEADACHE
HEADACHE
 
Refractory epilepsy
Refractory epilepsy Refractory epilepsy
Refractory epilepsy
 
Refractory epilepsy
Refractory epilepsy Refractory epilepsy
Refractory epilepsy
 
Treatment of epilepsy
Treatment of epilepsyTreatment of epilepsy
Treatment of epilepsy
 
EMBRYOLOGY OF BRAIN,NEW
EMBRYOLOGY OF BRAIN,NEWEMBRYOLOGY OF BRAIN,NEW
EMBRYOLOGY OF BRAIN,NEW
 
Management of epilepsy
Management of epilepsyManagement of epilepsy
Management of epilepsy
 
Stroke in children
Stroke in children Stroke in children
Stroke in children
 
Radiology of ventricles
Radiology of ventriclesRadiology of ventricles
Radiology of ventricles
 
EEG artifacts
EEG  artifactsEEG  artifacts
EEG artifacts
 
Prion diseases ---kuru
Prion diseases ---kuru Prion diseases ---kuru
Prion diseases ---kuru
 
presurgical evaluation of epilepsy
presurgical evaluation of epilepsypresurgical evaluation of epilepsy
presurgical evaluation of epilepsy
 
Neurology of heat stroke
Neurology of heat strokeNeurology of heat stroke
Neurology of heat stroke
 
Stroke in malignancy
Stroke in malignancyStroke in malignancy
Stroke in malignancy
 
CAROTID ARTERY STENOSIS
CAROTID ARTERY STENOSISCAROTID ARTERY STENOSIS
CAROTID ARTERY STENOSIS
 
heat stroke
heat strokeheat stroke
heat stroke
 
Brain death
Brain deathBrain death
Brain death
 

Clobazam

  • 2. 7-Chloro- 1-methyl- 5-phenyl- 1,5- benzodiazepine- 2,4(3H)-dione
  • 3. INTRODUCTION • synthesized in 1972 by modification of the 1,4-diazepine structure • The resulting 1,5 structure retained 20% of the the anxiolytic activity of diazepam,10-15 % of diazepam's sedative effects . • introduced as an anti-anxiety agent about half as potent as diazepam and producing less psychomotor side-effects than diazepam. • later found to have major antiepileptic effects
  • 4. CHEMISTRY • white hygroscopic powder with MW 300.73. • It has a bitter taste, is relatively insoluble in water • cannot be given as intravenous or intramuscular injection. • It is a weak organic acid and forms water-soluble salts at acidic pH. • At physiological pH its lipid solubility is about 40% of that of diazepam
  • 5. Mode of action • Clobazam exerts its anxiolytic and anticonvulsant action at the benzodiazepine binding site of the Gamma-aminobutyric acid A (GABA -A) receptor complex by increasing the likelihood of opening of the ligand-gated Cl~ ion channel in response to given concentration of GABA.
  • 6. • less affinity for the ω1-allosteric binding site on the GABAA receptor compared to the 1,4-benzodiazepines. • selective affinity for the ω2 site, where it has agonistic activity. • action at a lower affinity membrane site which probably involves an increase in the population of sodium channels in the inactive state, limiting the repetitive firing of neurones. • A decrease of voltage-sensitive Ca conductance is also observed, limiting Ca(++) entry presynaptically and decreasing neurotransmitter release
  • 7. Pharmacokinetics • absorbed rapidly and almost completely. • Mean absorption half-life is 20 min. • It is unaffected by age or sex. • The rate of absorption is reduced when the drug is taken with or after meals, but the extent of absorption is not . • The drug is highly lipophilic and, after absorption, is rapidly distributed in fat and cerebral grey matter.
  • 8. • Maximal plasma concentration after a single dose is seen after 1-4 h • half-lives varies from 11 to 77 h in healthy subjects, with the longest half-life in the elderly . • The half-life of clobazam's major metabolite, Ndesmethylclobazam is even longer, about 50 h. • At clinical doses , plasma concentration of the metabolite (300-3500ng/mL) is usually 10-fold greater than clobazam concentrations (20-350 ng/mL) . • good correlation between plasma concentration and dose in the individual patient but large interindividual variations. • Measurements of serum levels, however, have not been found useful clinically.
  • 9. • Plasma protein binding of the benzodiazepines varies from nearly 99% for diazepam to 70% for alprazolam. • Clobazam protein binding is 83%. • The protein bound fraction is independent of plasma concentration of clobazam • only changed by lowered protein content, which may be of importance in hepatic and renal diseases and other conditions with lowered protein, e.g. in the elderly.
  • 10. Drug interactions • has a complex pattern of interactions, with marked interindividual variability. • increase or decrease in the blood levels of phenobarbital, phenytoin or carbamazepine . • Phenytoin toxicity in patients on maximal tolerable phenytoin doses when clobazam was added • levels of all enzyme-inducing antiepileptic drugs can alter in susceptible patients. • The combination of valproate in doses of 1500-2000 mg and clobazam leads to an increase in serum valproate levels often with toxic-confusional states • These rather unpredictable interactions may be the explanation for the aversion to clobazam shown by some patients with chronic epilepsy on antiepileptic polytherapy.
  • 11. • Clobazam levels are generally lower and norclobazam levels higher in patients who are comedicated with enzyme-inducing antiepileptic drugs. • Comedication with carbamazepine seems to induce the epoxidation of this drug • Conversely, it has also been reported that clobazam levels can be raised in bitherapy with phenobarbital, phenytoin and carbamazepine . • Concomitant administration of alcohol and cimetidine can also lead to a significant increase in clobazam levels.
  • 12. Biotransformation • Clobazam is metabolized to least 12 metabolites. • biotransformation of clobazam is by oxidation in the liver to desmethylclobazam (norclobazam), an active metabolite. • Norclobazam may be responsible for the effects of clobazam . serum concentrations are usually over 10-fold higher than the parent drug. • Studies in baboons have shown antiepileptic effects 5-6 h after IV infusion, by which time clobazam plasma concentrations have fallen to low levels. • the lipophilicity of norclobazam is lower than that of clobazam, and the affinity for the benzodiazepine receptor is more than 10-fold lower than that of clobazam. • Desmethylclobazam is further metabolized by conjugation and excreted in bile as glucuronate and in bile and urine as the sulphate
  • 14. Toxicity • sedation, development of tolerance and withdrawal symptoms can limit the use of 1,4 benzodiazepines in chronic treatment of epilepsy, • clobazam has less detrimental effects on psychomotor performance than these drugs . • Impairment on a few cognitive tests, mainly retrieval processes and mental rapidity has been reported . • Muscle fatigue or weakness is an effect apparent in dynamic work situations where a disorderly recruitment of motor units is seen .
  • 15. • Significant toxicity includes sedation, dizziness, headache, nausea, amnesia, ataxia and blurred vision or diplopia. • In chronic institutionalized patient populations increased irritability, depression and disinhibition occurs and behaviour disturbance may be seen. . • Drowsiness and dizziness were the most common side- effects. • Gelastic seizures,Urticaria ,Rashes,are rare side effects • side-effects were mild and transient, and seems well tolerated. • The plasma concentration of the metabolite norclobazam is increased significantly in polytherapy, and this may be the cause of some of the sedative side-effects
  • 17. Tolerance • Tolerance or 'escape' is usually measured as an increase of seizure frequency in the last half of a treatment period, • Tolerance is increased by high doses, and decreased by intermittent treatment • In patients with temporal lobe epilepsy tolerance was found to be increasing slowly from 3% after 1 month to 35% after 2 years and did not seem to increase further • Used as monotherapy in childhood epilepsy, tolerance was noted in7 .5%, as compared to 4.3% for carbamazepine and 6.7% for phenytoin monotherapy . • Tolerance to sedation develops more quickly than tolerance to the anticonvulsant or anxiolytic effects
  • 18. withdrawal • Withdrawal symptoms with irritability, restlessness and difficulty to concentrate appears in 5-10% during the first 14 days after termination of treatment. • Tapering will in most cases prevent this.
  • 20. Antiepileptic effectiveness • tried in patients with refractory epilepsy of long standing as an addition to other antiepileptic treatment. • Patients of all ages, aetiologies and seizure types responded. • Some consider partial seizures to do best, and others secondarily generalized attacks. • It has been claimed that patients with symptomatic epilepsy, most often with partial seizures without secondary generalization and without mental retardation, respond best to clobazam , but this is an uncontrolled observation which has not been replicated
  • 21. adjunctive therapy in • complex partial seizures • myoclonic, • myoclonic-absent, • simple partial, • non-status absence seizures
  • 22. Open studies reported a beneficial and even astounding effect in • non-convulsive status, • startle seizures , • Lennox-Gastaut syndrome • alcoholic withdrawal seizures , Studies of clobazam used as monotherapy are very few. Clobazam has, however, been used in open studies as the only drug in benign childhood partial epilepsy and found of value even in carbamazepine-resistant cases .
  • 23. Uncontrolled observations (as well as routine clinical experience) show good efficacy • acute epilepsy, • clusters, • serial seizures • prophylaxis (e.g. on days when it is important to avoid a seizure such as when travelling, taking examinations, interviews, etc.). • Clobazam is the drug of first choice for such intermittent therapy • intermittent therapy in catamenial epilepsy
  • 24. Dose and clinical therapeutics • 5 to 140 mg/day. • There is now general agreement that doses between 10 and 20 mg/day (in adults) are usually best, • few patients who continue to have seizures respond better to higher doses, • Dose adjustments are not usually needed in patients comedicated with other antiepileptic drugs. • The frequency of side-effects increases sharply with higher doses (above 30mg/day). • The usual daily dose for acute prophylaxis is lOmg. • Clobazam withdrawal should be carried out slowly in a staged fashion.